companiesCompany
Merus
Dutch bispecific antibody company behind zenocutuzumab and petosemtamab; acquired by Genmab in 2025.
Biclonics platform; zenocutuzumab (NRG1 fusions, approved 2024, expanded 2026), petosemtamab (EGFR×LGR5, phase 3 in head and neck and colorectal cancer). Genmab announced acquisition for ~$8B in 2025.
ApprovedBispecific antibody (HER2×HER3)
Zenocutuzumab · Bizengri
Zenocutuzumab is the first drug for cancers driven by NRG1 gene fusions, working by blocking HER3 from receiving its growth signal.
Phase 3Bispecific antibody (EGFR × LGR5)
Petosemtamab
A two-armed antibody that blocks EGFR while gripping LGR5, a marker of cancer stem cells, so it hits the cells that regrow tumours.